About half of human solid tumors carries p53 mutations, which are usually associated with cancer aggressiveness and poor outcome, but rarely occurring in TGCTs (1-5%) [8, 9] ; a distinctive element in TGCT, unlike other malignancies, is the lack of correlation between immunohistochemical p53 overexpression and mutation [10, 11], with high levels of wild-type p53 protein [12, 13] . The gene discussed is TP53; the disease is cancer.